Vertex Pharmaceuticals Ownership
| VRTX Stock | USD 459.00 3.58 0.77% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 258 M | Current Value 261 M | Avarage Shares Outstanding 237.8 M | Quarterly Volatility 27.2 M |
Vertex |
Vertex Stock Ownership Analysis
About 96.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.27. Vertex Pharmaceuticals recorded a loss per share of 2.07. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 24th of August 2000. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 00 people. For more information please call MD FASN at 617 341 6100 or visit https://www.vrtx.com.Besides selling stocks to institutional investors, Vertex Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Vertex Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Vertex Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Vertex Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Vertex Pharmaceuticals Insider Trades History
Less than 1% of Vertex Pharmaceuticals are currently held by insiders. Unlike Vertex Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Vertex Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Vertex Pharmaceuticals' insider trades
Vertex Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vertex Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vertex Pharmaceuticals backward and forwards among themselves. Vertex Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Vertex Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Loomis, Sayles & Company Lp | 2024-12-31 | 3.8 M | Norges Bank | 2024-12-31 | 3.4 M | Amundi | 2024-12-31 | 3.3 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 3 M | Bank Of America Corp | 2024-09-30 | 2.6 M | Hhg Plc | 2024-09-30 | 2.5 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 2.4 M | Northern Trust Corp | 2024-09-30 | 2.4 M | Massachusetts Financial Services Company | 2024-12-31 | 2.3 M | Capital World Investors | 2024-12-31 | 28.3 M | Vanguard Group Inc | 2024-12-31 | 23.3 M |
Vertex Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vertex Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vertex Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vertex Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bozic Carmen over three months ago Disposition of 2812 shares by Bozic Carmen of Vertex Pharmaceuticals at 420.58 subject to Rule 16b-3 | ||
Charles Wagner over a year ago Sale by Charles Wagner of 3000 shares of Vertex Pharmaceuticals | ||
Charles Wagner over a year ago Payment of 2707 shares by Charles Wagner of Vertex Pharmaceuticals subject to Rule 16b-3 |
Vertex Pharmaceuticals' latest congressional trading
Congressional trading in companies like Vertex Pharmaceuticals, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Vertex Pharmaceuticals by those in governmental positions are based on the same information available to the general public.
| 2024-12-06 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
| 2024-10-08 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
| 2024-06-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2024-06-13 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2015-05-27 | Senator John Reed | Acquired Under $15K | Verify |
Vertex Pharmaceuticals Outstanding Bonds
Vertex Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vertex Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vertex bonds can be classified according to their maturity, which is the date when Vertex Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| VERTICAL HOLDCO GMBH Corp BondUS92537VAA89 | View | |
| VERTICAL U S Corp BondUS92537RAA77 | View | |
| US92535UAB08 Corp BondUS92535UAB08 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Vertex Pharmaceuticals Corporate Filings
F4 | 14th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 13th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 12th of February 2025 Other Reports | ViewVerify | |
8K | 10th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.